Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder
Qunlian Huang,1 Xiaoyan Zhong,1 Ye Yun,1 Bin Yu,2 Yilan Huang1 1Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, 2Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan Province, People’s Republic of China Object...
Guardado en:
Autores principales: | Huang Q, Zhong X, Yun Y, Yu B, Huang Y |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/db5d6893455c4d9fb46afab643defdfb |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical and Neurocognitive Predictors of Functional Outcome in Depressed Patients with Partial Response to Treatment: One Year Follow-Up Study
por: Castellano S, et al.
Publicado: (2020) -
The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
por: Li G, et al.
Publicado: (2016) -
Pioglitazone could induce remission in major depression: a meta-analysis
por: Colle R, et al.
Publicado: (2016) -
Elevated peripheral blood glutamate levels in major depressive disorder
por: Inoshita M, et al.
Publicado: (2018) -
The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
por: McIntyre RS
Publicado: (2017)